Biotech.
Company
- Reports this week
- 0
- Active events
- 0
- Connections
- 43
What's happening
One to three months ago
-
The biotech sector relies on market infrastructure for raising capital.Some support2 reports2 developments inside
-
Policymakers are considering ways to influence the drug market, including potential changes to patent rights and the FDA approval process.Some support3 reports
-
Amgen is classified as biotech for legacy reasons, a classification influenced by past failures experienced in London.Some support1 report
-
The SEC legally requires fiduciaries to prioritize client interests, while specific ETFs like XBI offer equal-weighted exposure to biotech and hedge against AI concentration risk.Some support2 reports
Gone quiet
No new reports in 90+ days-
M&A activity is driving sector recovery.Some support1 report1 development inside
-
Structure Therapeutics is an early-stage business operating within the biotech sector.Speculative1 report
-
Gains in Big Tech shares fueled market rise, while biotech company Enveda reached a billion-dollar valuation and a new international equity ETF was launched.Some support1 report
-
EIT Food is discussing the shift towards biotech-driven approaches to address climate change impacts on Arabica coffee yields.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Biotech this week
News at the entities that move Biotech most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Biotech
-
Massachusetts StructuralAn unnamed entity (T) is considering Keolis for a new contract in Massachusetts, while also warning about economic operational risks and providing advisory on operational costs.Moves Biotech
-
Goldman Sachs Mentioned togetherGoldman Sachs, Morgan Stanley, JPMorgan Chase, and Bank of America are competing in the global investment banking sector.Moves Biotech
-
Moderna OperationalAnalyst downgrades and market challenges are impacting Moderna amid waning demand for COVID-19 vaccines, alongside pipeline successes.Moves Biotech
-
Congress StructuralMandated National Bridge Inspection Standards were established in 1968.Moves Biotech
-
ICON plc OperationalICON plc, led by CEO Steve Cutler, operates out of its headquarters in Dublin, Ireland.Moves Biotech
Connections
The 18 strongest of 43, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
The FDA functions as the essential regulatory gatekeeper whose approvals and delays dictate the market viability of biotech companies.
-
Moderna Operational
Both companies operate within the mRNA therapeutics and vaccine market, sharing a focus area and responding to global health crises like COVID-19.
-
Massachusetts Structural
Massachusetts state tax laws structurally impact the R&D incentives of biotech companies.
-
ICON plc Operational
Both companies operate within the same Pharma/Biotech market segment, indicating active market interaction and potential competition.
-
EIT Food Structural
one depends on the other
-
Goldman Sachs Mentioned together
Goldman Sachs provides analysis and commentary on the performance and valuation of the Biotech sector.
-
Vertex Pharmaceuticals Shared context
Vertex Pharmaceuticals is identified as a major holding within the broader biotech sector ETF.
-
Amgen Mentioned together
Amgen is classified and listed within the broader Biotech sector.
Show all 18 connections
-
Congress Structural
Biotech is subject to formal regulation by Congress, which is considering changes to patent rights.
-
Incyte Mentioned together
Biotech is mentioned in the M&A context of Incyte.
-
Gilead Sciences Mentioned together
Gilead Sciences is cited as a member of the Biotech sector.
-
Nasdaq Shared context
Biotech companies operate within the market structure provided by Nasdaq, which serves as a major listing exchange.
-
AbbVie Shared context
AbbVie is identified as a company operating within the Biotech sector.
-
London Shared context
Past failures in London influenced the sector prejudice of the Biotech industry.
-
Halozyme Therapeutics Mentioned together
Halozyme Therapeutics is classified as a biopharma technology platform company, placing it within the broader biotech sector.
-
FED Mentioned together
The provided evidence focuses solely on the FED's response to inflation and tariffs, showing no direct coupling or relationship with Biotech.
-
Arabica Mentioned together
no direct coupling
-
Barry Callebaut Mentioned together
The evidence establishes that companies like Barry Callebaut are attracted to cultivated coffee, but does not define a specific relationship between Biotech and Barry Callebaut.
History
Events by the month they beganAugust 2026
1 eventJuly 2026
3 events- The biotech sector relies on market infrastructure for raising capital.
- Amgen is classified as biotech for legacy reasons, a classification influenced by past failures experienced in London.
- The SEC legally requires fiduciaries to prioritize client interests, while specific ETFs like XBI offer equal-weighted exposure to biotech and hedge against AI concentration risk.
June 2026
4 events- M&A activity is driving sector recovery.
- Structure Therapeutics is an early-stage business operating within the biotech sector.
- Gains in Big Tech shares fueled market rise, while biotech company Enveda reached a billion-dollar valuation and a new international equity ETF was launched.
- EIT Food is discussing the shift towards biotech-driven approaches to address climate change impacts on Arabica coffee yields.